Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXOPEDI
- Development stage
- Preclinical
- Lead developer
- EXO Biologics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
01
Overview
EXOPEDI is an exosome-based therapy developed by Dermama Biotechnology, derived from human Wharton's Jelly (HUC-WJ). It is specifically designed for the treatment of pediatric neurodevelopmental syndromes in patients aged 0 to 18 years. The therapy leverages the regenerative and paracrine factors naturally packaged within exosomes to support neural development and repair. As a cell-derived product, EXOPEDI does not have a single defined molecular target but instead acts through a complex interplay of proteins, lipids, and nucleic acids to provide therapeutic benefits in neurodevelopmental conditions.
- Brand names
- EXOPEDI
Beyond the preview
Go deeper on EXOPEDI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXOPEDI.